Tag Archives: Gilead

CNN reports: Two shots a year of a drug currently used to treat HIV infections were dramatically effective at preventing infections in a study among young women and adolescent girls in Africa. The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and published …

Courthouse News reports: Pharmaceutical giant Gilead Sciences triumphed over consumers Friday in a closely watched, yearslong class action that claimed the company deliberately manipulated the market in order to profit off of its highly-priced HIV treatment drugs. Closing arguments in a six-week trial wrapped Wednesday, leaving a federal jury to consider weeks of evidence regarding the pharmaceutical giant’s conduct and …

Panama City’s NBC News affiliate reports: Dozens of books were recently taken off Walton County schools library shelves, leading to concern on social media and during the school board meeting Tuesday. District officials confirmed 58 were removed from libraries throughout all schools. “I did it for just a welfare of all involved, including our constituents, our teachers, and our students. …

The Associated Press reports: Gilead Sciences Inc said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years, endangering patients. The drugmaker said it found 85,247 bottles that had been tampered with or faked, including versions of its Biktarvy and Descovy treatments. In a …

The Associated Press reports: The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. Gilead Sciences announced the price Monday for remdesivir, and said the price would be $3,120 for …

STAT News reports: Seeking to blunt concerns about access to its remdesivir treatment for Covid-19, Gilead Sciences (GILD) signed deals with five generic companies in India and Pakistan to manufacture and distribute the experimental medicine to 127 countries. Under the agreements, the companies can set their own prices, but will not have to pay royalties to Gilead until the World …

CNBC reports: The Food and Drug Administration has granted emergency use authorization for Gilead Sciences remdesivir drug to treat the coronavirus, President Donald Trump announced Friday. Trump made the announcement in the Oval Office alongside Gilead CEO Daniel O’Day. “We want to thank the collaborators that brought remdesivir to this point and many of our people that have been part …

The Associated Press reports: An experimental drug has proved effective against the new coronavirus in a major study, shortening the time it takes for patients to recover by four days on average, U.S. government and company officials announced Wednesday. Gilead Sciences’s remdesivir is the first treatment to pass such a strict test against the virus, which has killed more than …

STAT News reports: A Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned. Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the …

Axios reports: Gilead Sciences CEO Daniel O’Day said in an open letter Saturday the company is expanding access to its experimental anti-coronavirus drug remdesivir to include severely ill COVID-19 patients. President Trump has called the antiviral drug “promising,” but the results of six clinical trials on this investigational medicine are still being conducted, so its effectiveness the treatment of the …

The Military Times reports: U.S. Army Medical Research and Development Command has signed an arrangement with Gilead Sciences to provide the company’s investigational coronavirus drug to U.S. troops confirmed to have the COVID-19 virus. Gilead’s medication, remdesivir, was approved for clinical research in February by the FDA. The medication, which initially was developed by the Foster City, California-based company to …

The Washington Post reports: In 2005, Gilead Sciences notified federal regulators that it was suspending development of a potentially safer, more potent HIV-fighting drug than the one on the market. The company did not restart its Food and Drug Administration application until 2010. Now the five-year delay of a promising drug is at the core of accusations by advocates that …

The New York Times reports: The Trump administration on Wednesday sued Gilead Sciences, a pharmaceutical company that sells H.I.V.-prevention drugs that can cost patients up to $20,000 a year, accusing the company of earning billions from research funded by taxpayers without paying taxpayers back. The government said the company infringed upon patents owned by the Department of Health and Human …

NBC News reports: Gilead Sciences, the drug giant behind the blockbuster HIV prevention pill Truvada, won FDA approval on Thursday to market Descovy — a medication already used by those who have HIV — as its next-generation prevention drug. The final approval follows an August vote in favor of Descovy as a pre-exposure prophylaxis medication, or PrEP, by an FDA …

The Washington Post reports: The chairman of the House Oversight Committee is expanding the committee’s review of Gilead Science’s patent claims relating to Truvada for PrEP, the company’s drug that prevents HIV infection. In a letter released Thursday, Rep. Elijah E. Cummings (D-Md.) demanded emails and other information from Gilead about negotiations that led to Gilead’s pledge to donate free …

The Hill reports: Republican members of Congress defended Gilead, the leading manufacturer of HIV drugs in the U.S., during a testy hearing Thursday focused on the prices of its products. “I just cannot understand why we are spending time sitting here listening to people lecturing companies about making money. I hope you make a lot of money,” Rep. Chip Roy …

The Washington Post reports: The chief executive of Gilead Sciences, the nation’s leading manufacturer of HIV drugs, insisted before a House committee Thursday that a government patent on Truvada, a key drug that prevents the infection, is invalid. “Our well-supported view is that the U.S. government does not hold valid patents on the use of Truvada for pre-exposure prophylaxis (‘PrEP’), …

STAT News reports: In a bid to maintain its dominance in the HIV market, Gilead Sciences (GILD) allegedly conspired with other drug makers whose medicines were part of a so-called combination cocktail in order to block generic competition, according to a lawsuit filed by AIDS activists and two unions. The complaint describes an unusual scheme concerning these cocktails, which are …

Via press release: Health and Human Services Secretary Alex M. Azar II announced today that, as a result of discussions between the Trump Administration and Gilead Sciences, Inc., the pharmaceutical company has agreed to donate pre-exposure prophylaxis (PrEP) medication for up to 200,000 individuals each year for up to 11 years. PrEP is used to reduce the risk of HIV …

Gay Star News reports: Britain’s High Court today ruled to overturn pharmaceutical company Gilead Science’s patent extension on Truvada. The HIV medication is also used for PrEP (Pre-Exposure Prophylaxis). When taken as advised, this stops HIV negative people acquiring HIV. PrEP is not yet available on the NHS in England and Wales. The NHS is currently conducting a trial to …